Key Takeaways
- Aflibercept 8 mg was associated with low rates of adverse events in a real-world cohort of 1,429 eyes with nAMD.
- No cases of retinal vasculitis or retinal vascular occlusion were reported, and rates of intraocular inflammation and symptomatic IOP increases were low.
Low rates of adverse events among patients with neovascular age-related macular degeneration (nAMD) treated with aflibercept 8 mg were found in a real-world case series.
Researchers retrospectively reviewed safety data from a Danish tertiary retina clinic after systematically switching patients with nAMD to aflibercept 8 mg. The analysis included 8,675 intravitreal injections administered in 1,429 eyes, including 139 eyes with glaucoma.
Twenty-five adverse events were reported among 8,675 injections (2.88 per 1,000 injections). Intraocular inflammation occurred in 11 eyes (1.27 per 1,000 injections). Most cases were managed with topical dexamethasone, and 1 patient required vitrectomy. Symptomatic intraocular pressure elevation was reported in 10 cases (1.15 per 1,000 injections). Rates of symptomatic intraocular pressure increase did not differ significantly between glaucomatous and non-glaucomatous eyes.
Two cases of bacterial endophthalmitis were identified during the study period. No cases of retinal vasculitis or retinal vascular occlusion were observed.
Reference
Karunainathan MG, Lee C, Zohalinejad KD, et al. Real-world insights on switching aflibercept dosage for enhanced outcomes in age-related macular degeneration (RISE-AMD): Safety data. Acta Ophthalmol. 2026;doi: 10.1111/aos.70160. Epub ahead of print. PMID: 42199036.
Related Content
